Welcome to our dedicated page for Castle Biosciences SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Castle Biosciences’ genomic tests for melanoma, ophthalmology and gastroenterology come with layers of clinical trial data, reimbursement disclosures and risk factors. Finding the impact of a new Medicare rule or evaluating pipeline milestones inside a 300-page report can feel overwhelming.
Our platform solves that problem. Stock Titan’s AI reads every Castle Biosciences SEC filing the moment it hits EDGAR and delivers plain-English answers. Whether you need the Castle Biosciences quarterly earnings report 10-Q filing for revenue-per-test trends or want Castle Biosciences insider trading Form 4 transactions before the market opens, the information is distilled into concise summaries, key metrics and red-flag alerts.
- AI highlights reimbursement commentary buried in the Castle Biosciences annual report 10-K simplified.
- Real-time alerts surface Castle Biosciences Form 4 insider transactions real-time so you can track executive sentiment.
- One-click access to the Castle Biosciences proxy statement executive compensation helps you benchmark management incentives.
- Need context on FDA news? The platform provides Castle Biosciences 8-K material events explained in seconds.
Because our AI understands oncology terminology, understanding Castle Biosciences SEC documents with AI becomes straightforward. Use the built-in tools for Castle Biosciences earnings report filing analysis, compare segment margins, or export data tables to your model—no manual copy-and-paste.
From Castle Biosciences SEC filings explained simply to tracking Castle Biosciences executive stock transactions Form 4, this page is your complete, continuously updated resource for every 10-K, 10-Q, 8-K, S-8 and beyond.
Castle Biosciences, Inc. (CSTL) – Form 144 overview
The filing reports a proposed sale of 16,932 common shares by insider-related entities, to be executed through Goldman Sachs & Co. LLC around 27 June 2025. At the most recent share count disclosed in the notice (28,872,315 shares outstanding), the planned disposition represents roughly 0.06 % of total shares, indicating a limited potential impact on the public float.
Historical sales disclosed for the preceding three months total 11,288 shares spread across multiple Maetzold family trusts, yielding aggregate gross proceeds of approximately $226,000 (sum of line-item figures). No additional company financial metrics, earnings data, or operational updates are provided in this Form 144.
Key takeaways for investors
- The filing signals continual, but small-scale, insider selling activity.
- Because the quantity is less than 0.1 % of shares outstanding, market impact is expected to be minimal under normal trading volumes.
- No mention is made of a Rule 10b5-1 trading plan; however, the signee affirms lack of undisclosed material adverse information as required by Rule 144.
Overall, the notice is routine and does not, on its own, imply any change in Castle Biosciences’ fundamentals or forward outlook.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
What is the primary focus of Castle Biosciences?
How does Castle Biosciences incorporate genomic information in its diagnostics?
Which cancer types does Castle Biosciences target with its tests?
What differentiates Castle Biosciences' diagnostic tests from others in the market?
How does Castle Biosciences maintain clinical relevance in its test development?
What types of diagnostic offerings does the company provide beyond cancer testing?
